2. Hochberg Y, Benjamini Y: More Powerful Procedures for Multiple Significance Testing

Supplementary table 3B: False Discovery Rates (FDRs) associated with vaccination-induced activities (FDR < 0.05 for at least one of the condition) for the Blood Transcriptional Modules (BTMs) defined in . QuSAGE was used to obtain P values for detecting the activity of each module by comparing pre- and post- vaccination transcriptional profiles. FDRs were obtained using the method of Benjamini and Hochberg .

Young Older Frail R+ R+ R+ R- R- R- R+ R+ R+ R- R- R- R- R- R- Days post-vaccination 2 7 28 2 7 28 2 7 28 2 7 28 2 7 28 Activated (LPS) dendritic cell surface 9.4E- 8.2E- 8.1E 5.9E- 9.7E- 6.1E- 8.6E 8.9E- 3.0E- 1.5E 5.6E- 1.5E- 1.0E+ 9.9E- 1.0E+ signature (S11) 01 01 -01 01 01 01 -01 01 01 -03 05 02 00 01 00 activated dendritic cells 7.0E- 6.0E- 9.6E 4.6E- 6.7E- 2.5E- 4.7E 8.0E- 7.2E- 8.9E 3.0E- 1.2E- 1.0E+ 9.9E- 1.0E+ (M67) 01 02 -01 01 01 01 -01 01 01 -02 01 02 00 01 00 antigen presentation (lipids and proteins) 9.4E- 3.0E- 2.5E 9.6E- 5.2E- 1.2E- 3.1E 3.7E- 9.8E- 1.0E 1.2E- 1.2E- 1.0E+ 9.9E- 1.0E+ (M28) 01 02 -02 01 01 01 -01 01 01 -04 02 02 00 01 00 antigen processing and 7.3E- 9.0E- 4.5E 8.6E- 4.6E- 1.0E+ 2.6E 1.9E- 9.4E- 2.0E 2.2E- 6.6E- 1.0E+ 9.9E- 1.0E+ presentation (M200) 01 02 -03 01 01 00 -01 01 01 -04 04 04 00 01 00 antiviral IFN signature 9.7E- 1.2E- 1.8E 6.1E- 5.7E- 4.4E- 2.7E 9.4E- 7.7E- 1.1E 2.7E- 7.7E- 1.0E+ 9.9E- 1.0E+ (M75) 01 03 -03 01 02 03 -01 01 01 -03 02 01 00 01 00 AP-1 transcription 7.0E- 9.6E- 1.6E 8.7E- 7.9E- 1.4E- 1.5E 3.4E- 8.1E- 4.3E 3.8E- 4.1E- 1.0E+ 9.9E- 1.0E+ factor network (M20) 01 04 -01 01 01 01 -01 01 01 -02 03 01 00 01 00 7.1E- 9.4E- 6.7E 1.2E- 9.6E- 9.8E- 3.7E 4.9E- 7.9E- 3.8E 4.8E- 6.3E- 1.0E+ 1.0E+ 1.0E+ axon guidance (M110) 01 01 -01 01 01 01 -01 01 01 -01 02 02 00 00 00 B cell development 1.0E+ 1.6E- 5.9E 9.2E- 2.6E- 3.8E- 5.0E 7.9E- 7.0E- 2.3E 2.4E- 1.4E- 1.0E+ 9.9E- 1.0E+ (M9) 00 02 -02 01 01 01 -01 01 01 -03 01 01 00 01 00 B cell development/activation 9.4E- 6.6E- 2.9E 7.6E- 5.8E- 2.2E- 7.4E 7.9E- 5.2E- 7.0E 1.4E- 4.6E- 1.0E+ 9.9E- 1.0E+ (M58) 01 01 -01 01 02 02 -01 01 01 -01 02 02 00 01 00 B cell surface signature 9.9E- 3.1E- 2.2E 2.0E- 5.1E- 6.6E- 2.0E 3.7E- 1.0E+ 1.3E 5.2E- 2.0E- 1.0E+ 9.9E- 1.0E+ (S2) 01 01 -01 02 05 06 -01 01 00 -02 04 01 00 01 00 9.9E- 1.6E- 7.7E 7.6E- 9.7E- 9.8E- 2.6E 6.2E- 8.1E- 5.9E 6.0E- 2.4E- 1.0E+ 9.9E- 1.0E+ BCR signaling (M54) 01 02 -03 01 01 01 -01 01 01 -04 01 02 00 01 00 blood coagulation 7.0E- 9.6E- 1.1E 6.9E- 2.2E- 2.3E- 1.1E 8.9E- 5.1E- 1.5E 1.9E- 1.5E- 1.0E+ 9.9E- 1.0E+ (M11.1) 01 04 -03 02 01 03 -01 01 01 -07 07 07 00 01 00 CD1 and other DC 7.0E- 1.5E- 7.3E 1.1E- 8.7E- 3.5E- 4.5E 9.4E- 8.1E- 1.1E 3.6E- 7.8E- 1.0E+ 9.9E- 1.0E+ receptors (M50) 01 02 -03 01 01 01 -01 01 01 -03 02 03 00 01 00 CD28 costimulation 7.0E- 3.8E- 1.7E 9.1E- 1.5E- 8.9E- 4.1E 9.4E- 9.7E- 6.4E 2.3E- 3.7E- 1.0E+ 9.9E- 1.0E+ (M12) 01 03 -03 01 01 03 -01 01 01 -04 02 04 00 01 00 CD4 T cell surface signature Th1- 8.5E- 3.0E- 6.9E 1.1E- 1.6E- 7.8E- 7.4E 8.6E- 7.0E- 2.8E 2.4E- 5.0E- 1.0E+ 9.9E- 1.0E+ stimulated (S6) 01 01 -01 01 02 04 -01 01 01 -02 02 04 00 01 00 CD4 T cell surface signature Th2- 8.6E- 2.2E- 6.5E 9.3E- 9.7E- 6.7E- 7.3E 3.4E- 3.7E- 7.4E 1.2E- 5.8E- 1.0E+ 9.9E- 1.0E+ stimulated (S7) 01 02 -03 01 01 01 -01 01 01 -04 01 03 00 01 00 cell activation (IL15, 7.1E- 1.9E- 1.3E 3.9E- 1.3E- 7.3E- 1.2E 8.9E- 8.1E- 1.8E 7.7E- 1.3E- 1.0E+ 9.9E- 1.0E+ IL23, TNF) (M24) 01 03 -02 01 03 04 -01 01 01 -04 01 02 00 01 00 cell adhesion (GO) 9.6E- 1.4E- 1.2E 6.2E- 7.5E- 1.6E- 1.7E 6.5E- 5.1E- 1.1E 1.4E- 3.4E- 1.0E+ 9.9E- 1.0E+ (M117) 01 03 -02 01 05 04 -02 01 01 -03 02 01 00 01 00 cell adhesion (lymphocyte homing) 9.4E- 4.7E- 8.3E 4.8E- 2.8E- 3.0E- 9.1E 6.5E- 9.4E- 7.6E 2.7E- 3.1E- 1.0E+ 9.9E- 1.0E+ (M21) 01 01 -01 01 01 02 -01 01 01 -01 02 02 00 01 00 6.4E- 3.3E- 5.1E 4.5E- 9.7E- 3.0E- 7.3E 9.4E- 9.4E- 2.5E 5.4E- 1.9E- 1.0E+ 9.9E- 1.0E+ cell adhesion (M51) 01 01 -03 02 01 02 -01 01 01 -02 06 05 00 01 00 cell cell adhesion 7.1E- 6.7E- 2.3E 6.1E- 6.7E- 6.9E- 7.0E 9.3E- 7.2E- 2.7E 5.2E- 7.6E- 1.0E+ 9.9E- 1.0E+ (M133.1) 01 01 -01 01 01 01 -01 01 01 -02 01 02 00 01 00 6.4E- 5.5E- 4.5E 9.0E- 3.4E- 1.6E- 1.2E 1.4E- 9.1E- 7.0E 5.2E- 9.9E- 1.0E+ 9.9E- 1.0E+ cell cycle (I) (M4.1) 01 05 -04 01 02 02 -01 01 02 -11 03 07 00 01 00 8.0E- 2.0E- 3.3E 8.7E- 5.9E- 8.8E- 7.4E 1.8E- 2.1E- 1.1E 9.9E- 7.7E- 1.0E+ 9.9E- 1.0E+ cell cycle (II) (M4.10) 01 02 -01 01 01 01 -01 01 01 -01 01 01 00 01 00 9.7E- 1.9E- 1.2E 6.9E- 4.9E- 2.6E- 8.7E 4.9E- 4.4E- 3.0E 1.8E- 7.8E- 1.0E+ 9.9E- 1.0E+ cell cycle (III) (M103) 01 03 -02 01 01 02 -01 01 01 -03 01 03 00 01 00 cell cycle and growth 6.4E- 2.6E- 3.0E 4.4E- 1.2E- 1.6E- 3.3E 7.9E- 9.5E- 4.0E 8.8E- 2.3E- 1.0E+ 9.9E- 1.0E+ arrest (M31) 01 04 -02 01 01 03 -02 01 01 -05 01 03 00 01 00 cell cycle and 7.1E- 3.0E- 3.7E 1.1E- 4.3E- 1.6E- 1.7E 4.6E- 3.3E- 3.4E 4.5E- 5.6E- 1.0E+ 9.9E- 1.0E+ transcription (M4.0) 01 03 -05 04 04 08 -02 01 01 -12 12 12 00 01 00 cell cycle, ATP binding 8.8E- 4.1E- 7.4E 1.1E- 1.6E- 5.4E- 3.7E 2.6E- 8.1E- 3.5E 1.8E- 3.0E- 1.0E+ 6.3E- 1.0E+ (M144) 01 03 -04 01 02 05 -01 01 01 -06 01 03 00 01 00 cell cycle, mitotic phase 9.7E- 2.4E- 1.6E 3.7E- 2.9E- 1.3E- 6.2E 3.7E- 8.1E- 5.9E 8.1E- 4.4E- 1.0E+ 7.4E- 1.0E+ (M230) 01 03 -03 01 04 04 -01 01 01 -04 01 03 00 01 00 cell division (stimulated 9.7E- 1.9E- 9.8E 2.1E- 1.0E+ 8.9E- 2.7E 5.6E- 3.7E- 4.4E 9.9E- 6.0E- 1.0E+ 9.9E- 1.0E+ CD4+ T cells) (M46) 01 01 -01 01 00 01 -01 01 01 -02 02 02 00 01 00 cell division in stimulated CD4 T cells 6.4E- 3.0E- 8.0E 5.6E- 6.2E- 7.3E- 6.7E 4.0E- 2.2E- 1.4E 1.0E- 3.0E- 1.0E+ 9.9E- 1.0E+ (M4.6) 01 03 -02 01 01 01 -01 01 01 -04 03 03 00 01 00 cell junction (GO) 8.7E- 2.7E- 1.7E 3.3E- 4.3E- 1.5E- 8.6E 7.8E- 4.1E- 1.4E 2.6E- 4.7E- 1.0E+ 9.9E- 1.0E+ (M4.13) 01 03 -03 01 01 02 -02 01 01 -07 05 06 00 01 00 7.1E- 2.6E- 1.2E 8.7E- 9.7E- 9.2E- 7.6E 8.9E- 9.0E- 1.2E 3.3E- 3.7E- 1.0E+ 9.9E- 1.0E+ cell junction (M162.1) 01 02 -01 01 01 01 -01 01 01 -01 01 01 00 01 00 cell movement, Adhesion & Platelet 6.4E- 4.8E- 5.4E 6.9E- 8.7E- 8.6E- 9.9E 9.6E- 7.7E- 2.6E 1.6E- 3.6E- 1.0E+ 9.9E- 1.0E+ activation (M30) 01 02 -03 02 01 04 -01 01 01 -01 04 05 00 01 00 chaperonin mediated protein folding (I) 6.4E- 6.8E- 5.6E 9.2E- 8.6E- 1.9E- 7.8E 1.4E- 9.2E- 3.1E 1.1E- 1.1E- 1.0E+ 7.4E- 1.0E+ (M204.0) 01 04 -04 02 04 03 -02 01 01 -07 01 04 00 01 00 chaperonin mediated protein folding (II) 7.0E- 6.8E- 6.2E 5.2E- 5.2E- 1.6E- 4.6E 3.4E- 9.4E- 5.8E 7.9E- 7.6E- 1.0E+ 4.2E- 1.0E+ (M204.1) 01 04 -04 02 05 05 -02 01 01 -07 01 04 00 01 00 chemokine cluster (II) 9.9E- 9.7E- 4.6E 2.8E- 5.9E- 9.8E- 5.3E 6.5E- 9.5E- 6.7E 2.2E- 6.0E- 1.0E+ 9.9E- 1.0E+ (M27.1) 01 01 -01 01 02 01 -01 01 01 -01 04 01 00 01 00 chemokines and inflammatory molecules in myeloid 7.1E- 7.0E- 3.2E 5.9E- 1.1E- 5.5E- 3.4E 6.5E- 9.4E- 2.2E 4.7E- 3.7E- 1.0E+ 9.9E- 1.0E+ cells (M86.0) 01 04 -02 01 01 03 -02 01 01 -03 02 01 00 01 00 chemokines and 7.2E- 1.0E- 1.7E 6.0E- 4.3E- 1.9E- 1.9E 9.3E- 9.4E- 7.7E 7.7E- 2.0E- 1.0E+ 9.9E- 1.0E+ receptors (M38) 01 03 -01 01 01 01 -01 01 01 -03 01 01 00 01 00 C-MYC transcriptional 9.3E- 2.1E- 1.9E 8.7E- 1.8E- 2.3E- 3.9E 3.4E- 7.0E- 1.4E 4.3E- 1.6E- 1.0E+ 9.9E- 1.0E+ network (M4.12) 01 03 -02 01 01 01 -01 01 01 -03 01 01 00 01 00 collagen, TGFB family et 7.3E- 7.7E- 8.3E 3.9E- 8.8E- 2.9E- 4.7E 7.8E- 9.2E- 2.9E 2.4E- 2.4E- 1.0E+ 9.9E- 1.0E+ al (M77) 01 01 -01 01 01 01 -01 01 01 -01 02 02 00 01 00 complement activation 9.9E- 3.0E- 5.8E 8.7E- 6.5E- 5.1E- 8.5E 7.9E- 7.0E- 9.1E 3.3E- 5.8E- 1.0E+ 9.9E- 1.0E+ (I) (M112.0) 01 03 -02 01 02 02 -01 01 01 -03 02 02 00 01 00 complement and other 9.4E- 9.8E- 2.8E 8.4E- 3.3E- 5.3E- 8.7E 7.8E- 3.9E- 8.4E 5.4E- 1.7E- 1.0E+ 9.9E- 1.0E+ receptors in DCs (M40) 01 02 -02 01 01 01 -01 01 01 -05 05 02 00 01 00 CORO1A-DEF6 network 9.9E- 9.6E- 1.3E 4.0E- 5.2E- 2.8E- 1.7E 6.5E- 4.3E- 3.2E 1.4E- 4.2E- 1.0E+ 9.9E- 1.0E+ (I) (M32.2) 01 04 -03 01 05 05 -02 01 01 -07 03 02 00 01 00 CORO1A-DEF6 network 9.7E- 1.7E- 1.4E 6.7E- 3.9E- 5.4E- 4.1E 4.0E- 9.8E- 2.8E 1.7E- 3.4E- 1.0E+ 9.9E- 1.0E+ (II) (M32.4) 01 01 -02 01 01 02 -01 01 01 -04 02 01 00 01 00 cytokines - recepters 9.4E- 9.4E- 4.4E 8.7E- 3.5E- 7.4E- 5.6E 8.9E- 9.5E- 1.2E 9.8E- 1.3E- 1.0E+ 9.9E- 1.0E+ cluster (M115) 01 01 -01 01 01 01 -01 01 01 -02 02 01 00 01 00 cytoskeletal remodeling (enriched for SRF 6.4E- 9.2E- 1.7E 3.2E- 9.7E- 2.1E- 7.9E 8.9E- 9.0E- 2.3E 5.2E- 4.4E- 1.0E+ 9.9E- 1.0E+ targets) (M34) 01 01 -02 01 01 02 -01 01 01 -02 04 04 00 01 00 cytoskeletal remodeling 7.2E- 9.6E- 1.4E 1.3E- 3.9E- 1.4E- 3.4E 4.9E- 7.2E- 6.6E 4.7E- 2.3E- 1.0E+ 1.0E+ 1.0E+ (M32.8) 01 04 -03 01 04 03 -02 01 01 -05 01 02 00 00 00 cytoskeleton/actin (SRF transcription targets) 6.4E- 6.1E- 8.2E 1.9E- 6.2E- 3.8E- 7.0E 1.0E+ 9.0E- 6.9E 1.1E- 4.9E- 1.0E+ 9.9E- 1.0E+ (M145.0) 01 01 -02 01 01 01 -01 00 01 -02 02 03 00 01 00 cytoskeleton/actin (SRF transcription targets) 7.0E- 5.0E- 3.9E 8.1E- 4.0E- 4.8E- 9.4E 7.8E- 9.4E- 1.4E 9.1E- 1.4E- 1.0E+ 9.9E- 1.0E+ (M145.1) 01 01 -03 02 01 02 -01 01 01 -01 03 03 00 01 00 DC surface signature 7.1E- 8.3E- 6.6E 5.4E- 4.2E- 2.8E- 8.5E 7.8E- 6.9E- 3.3E 7.1E- 2.8E- 1.0E+ 9.9E- 1.0E+ (S5) 01 01 -01 01 02 02 -01 01 01 -04 07 06 00 01 00 9.0E- 1.0E- 7.1E 4.8E- 2.3E- 4.4E- 2.9E 4.9E- 7.0E- 1.4E 2.2E- 3.1E- 1.0E+ 9.9E- 1.0E+ DNA repair (M76) 01 02 -03 01 01 02 -01 01 01 -05 01 02 00 01 00 double positive 8.0E- 1.3E- 1.3E 9.2E- 5.5E- 9.2E- 7.4E 8.3E- 7.2E- 7.9E 5.8E- 2.4E- 1.0E+ 1.0E+ 1.0E+ thymocytes (M126) 01 01 -02 01 01 01 -01 01 01 -01 01 01 00 00 00 E2F1 targets (Q3) 9.7E- 2.3E- 4.9E 7.3E- 9.7E- 5.8E- 7.3E 6.8E- 3.7E- 2.5E 9.3E- 4.4E- 1.0E+ 9.9E- 1.0E+ (M10.0) 01 02 -02 01 01 02 -01 01 01 -01 01 01 00 01 00 E2F1 targets (Q4) 7.0E- 9.6E- 9.3E 3.9E- 1.2E- 4.5E- 9.1E 3.0E- 3.1E- 9.5E 6.1E- 5.6E- 1.0E+ 9.9E- 1.0E+ (M10.1) 01 04 -03 01 01 02 -01 01 01 -05 01 03 00 01 00 endoplasmic reticulum 7.2E- 3.0E- 2.5E 7.8E- 9.7E- 4.4E- 3.8E 9.5E- 5.1E- 2.7E 4.3E- 7.6E- 1.0E+ 9.9E- 1.0E+ (M37.2) 01 03 -02 01 01 01 -01 01 01 -04 03 03 00 01 00 enriched for cell 9.7E- 7.2E- 4.5E 6.9E- 3.9E- 9.3E- 8.6E 8.9E- 9.4E- 5.2E 2.4E- 2.4E- 1.0E+ 9.9E- 1.0E+ migration (M122) 01 01 -01 01 01 01 -01 01 01 -01 02 01 00 01 00 enriched for promoter motif NATCACGTGAY (putative SREBF1 8.0E- 2.3E- 1.4E 6.9E- 4.3E- 1.3E- 4.7E 8.4E- 9.4E- 8.4E 8.5E- 7.7E- 1.0E+ 9.9E- 1.0E+ targets) (M178) 01 02 -02 01 01 02 -01 01 01 -02 01 01 00 01 00 enriched for SMAD2/3 7.3E- 2.2E- 1.2E 4.1E- 4.5E- 1.4E- 1.2E 8.9E- 3.9E- 3.0E 6.9E- 9.6E- 1.0E+ 9.9E- 1.0E+ signaling (M97) 01 01 -01 01 02 02 -01 01 01 -01 01 01 00 01 00 enriched for TF motif 9.7E- 4.7E- 1.4E 2.1E- 7.1E- 4.8E- 1.9E 4.0E- 7.2E- 1.2E 2.6E- 1.6E- 1.0E+ 7.6E- 1.0E+ PAX3 (M179) 01 03 -03 01 03 04 -01 01 01 -05 01 03 00 01 00 enriched for TF motif 9.7E- 1.9E- 6.6E 9.1E- 7.3E- 2.1E- 3.0E 1.4E- 9.9E- 7.7E 1.0E+ 1.2E- 1.0E+ 7.4E- 1.0E+ TNCATNTCCYR (M232) 01 03 -03 01 03 02 -01 01 01 -03 00 02 00 01 00 enriched for TF motif TTCNRGNNNNTTC 7.5E- 1.4E- 9.2E 5.8E- 7.8E- 1.9E- 3.7E 9.8E- 9.2E- 2.9E 4.2E- 2.7E- 1.0E+ 9.9E- 1.0E+ (M172) 01 02 -02 01 01 01 -01 01 01 -01 01 01 00 01 00 enriched for 6.4E- 2.6E- 1.7E 8.8E- 1.3E- 2.2E- 4.3E 5.6E- 9.4E- 2.9E 2.0E- 2.8E- 1.0E+ 9.9E- 1.0E+ ubiquitination (M138) 01 02 -03 02 03 04 -02 01 01 -05 01 02 00 01 00 enriched in activated dendritic cells (I) 8.0E- 2.4E- 8.9E 5.8E- 5.7E- 7.3E- 6.3E 8.7E- 7.3E- 1.3E 5.9E- 1.4E- 1.0E+ 9.9E- 1.0E+ (M119) 01 02 -02 01 01 02 -01 01 01 -04 03 03 00 01 00 enriched in activated dendritic cells (II) 9.8E- 4.5E- 4.2E 7.7E- 3.0E- 6.0E- 4.6E 5.6E- 3.0E- 6.2E 7.1E- 1.0E- 1.0E+ 1.0E+ 1.0E+ (M165) 01 01 -01 01 02 01 -01 01 01 -01 03 01 00 00 00 enriched in activated dendritic 7.0E- 6.8E- 2.7E 4.6E- 9.1E- 1.9E- 1.2E 5.7E- 2.2E- 1.3E 9.0E- 4.0E- 1.0E+ 9.9E- 1.0E+ cells/monocytes (M64) 01 04 -02 01 01 02 -01 01 01 -05 03 04 00 01 00 enriched in antigen 7.2E- 9.6E- 3.6E 9.6E- 3.9E- 6.6E- 4.7E 3.7E- 9.4E- 2.5E 1.4E- 7.6E- 1.0E+ 9.9E- 1.0E+ presentation (I) (M71) 01 04 -03 01 01 02 -02 01 01 -06 04 04 00 01 00 enriched in antigen presentation (II) 8.0E- 1.2E- 1.6E 7.6E- 1.6E- 1.1E- 1.7E 8.5E- 9.5E- 3.2E 1.7E- 4.6E- 1.0E+ 9.9E- 1.0E+ (M95.0) 01 03 -03 01 02 02 -02 01 01 -07 02 02 00 01 00 enriched in antigen presentation (III) 8.0E- 4.8E- 2.0E 8.5E- 7.1E- 6.0E- 4.7E 4.9E- 9.7E- 2.7E 6.1E- 1.3E- 1.0E+ 9.9E- 1.0E+ (M95.1) 01 02 -02 01 01 01 -02 01 01 -05 03 02 00 01 00 enriched in B cell 7.0E- 1.3E- 3.9E 8.4E- 4.2E- 9.2E- 4.9E 8.9E- 8.8E- 4.8E 1.8E- 9.3E- 1.0E+ 9.9E- 1.0E+ differentiation (M123) 01 02 -01 01 01 01 -01 01 01 -01 01 01 00 01 00 enriched in B cells (I) 8.0E- 4.9E- 3.3E 4.3E- 2.5E- 1.2E- 1.2E 2.1E- 9.5E- 7.5E 4.2E- 3.5E- 1.0E+ 7.6E- 1.0E+ (M47.0) 01 02 -02 05 06 06 -02 02 01 -07 08 06 00 01 00 enriched in B cells (II) 8.4E- 4.5E- 8.2E 2.7E- 8.4E- 4.3E- 1.7E 1.4E- 9.6E- 4.6E 1.6E- 3.0E- 1.0E+ 7.6E- 1.0E+ (M47.1) 01 03 -02 03 06 06 -02 01 01 -05 06 04 00 01 00 enriched in B cells (III) 9.7E- 2.2E- 8.1E 4.4E- 5.2E- 1.6E- 2.5E 8.9E- 9.4E- 1.0E 6.5E- 4.8E- 1.0E+ 9.9E- 1.0E+ (M47.2) 01 02 -02 03 05 05 -01 01 01 -01 03 02 00 01 00 enriched in B cells (IV) 7.2E- 7.5E- 9.4E 9.2E- 8.2E- 1.5E- 7.1E 9.0E- 8.1E- 2.7E 9.6E- 7.4E- 1.0E+ 9.9E- 1.0E+ (M47.3) 01 03 -03 02 04 04 -02 01 01 -02 01 01 00 01 00 enriched in B cells (V) 9.6E- 7.0E- 2.7E 1.7E- 4.0E- 4.8E- 7.7E 8.9E- 7.3E- 2.9E 6.1E- 5.9E- 1.0E+ 9.9E- 1.0E+ (M47.4) 01 01 -02 01 01 02 -01 01 01 -01 03 02 00 01 00 enriched in B cells (VI) 9.7E- 9.7E- 3.4E 1.7E- 1.3E- 4.5E- 6.1E 3.6E- 8.1E- 6.6E 3.2E- 7.8E- 1.0E+ 7.9E- 1.0E+ (M69) 01 01 -01 02 03 04 -02 02 01 -03 05 03 00 01 00 enriched in cell cycle 7.0E- 3.3E- 1.4E 4.0E- 2.6E- 2.2E- 6.1E 8.0E- 5.1E- 7.9E 1.6E- 1.0E+ 1.0E+ 7.4E- 1.0E+ (M167) 01 01 -01 01 01 01 -01 02 01 -01 03 00 00 01 00 enriched in dendritic 7.0E- 4.5E- 7.1E 1.0E- 7.9E- 5.8E- 6.6E 7.7E- 6.8E- 1.8E 3.6E- 4.7E- 1.0E+ 9.9E- 1.0E+ cells (M168) 01 01 -01 01 01 01 -01 01 01 -04 05 05 00 01 00 enriched in DNA interacting proteins 9.4E- 1.0E- 2.0E 4.8E- 1.2E- 1.7E- 9.4E 4.0E- 7.2E- 9.7E 5.2E- 1.1E- 1.0E+ 9.9E- 1.0E+ (M182) 01 03 -03 01 03 04 -01 01 01 -03 01 01 00 01 00 enriched in extracellular matrix & associated 8.4E- 5.5E- 3.4E 4.6E- 6.8E- 2.0E- 9.6E 9.3E- 9.7E- 5.6E 2.5E- 4.9E- 1.0E+ 9.9E- 1.0E+ proteins (M202) 01 01 -02 01 01 01 -01 01 01 -01 02 02 00 01 00 enriched in G-protein coupled receptors 9.7E- 9.0E- 6.1E 1.8E- 2.5E- 7.0E- 8.1E 8.3E- 9.4E- 7.6E 1.0E- 2.6E- 1.0E+ 9.9E- 1.0E+ (M130) 01 01 -01 01 02 01 -01 01 01 -02 02 03 00 01 00 enriched in monocytes 9.4E- 3.1E- 6.1E 3.0E- 2.9E- 2.1E- 2.4E 4.6E- 5.1E- 1.5E 3.6E- 2.6E- 1.0E+ 9.9E- 1.0E+ (I) (M4.15) 01 02 -03 01 01 03 -01 01 01 -06 05 05 00 01 00 enriched in monocytes 6.4E- 3.1E- 3.3E 7.8E- 2.5E- 1.6E- 3.9E 5.6E- 3.9E- 1.6E 2.2E- 1.5E- 1.0E+ 9.9E- 1.0E+ (II) (M11.0) 01 06 -06 06 06 08 -04 01 03 -12 12 12 00 01 00 enriched in monocytes 7.0E- 1.3E- 3.3E 6.2E- 6.8E- 4.1E- 2.6E 9.0E- 2.6E- 2.2E 7.0E- 2.6E- 1.0E+ 9.9E- 1.0E+ (III) (M73) 01 02 -01 01 01 01 -01 01 01 -03 03 03 00 01 00 enriched in monocytes 6.4E- 2.1E- 1.3E 1.6E- 4.7E- 1.0E- 4.7E 6.0E- 1.1E- 2.1E 2.2E- 2.8E- 1.0E+ 9.9E- 1.0E+ (IV) (M118.0) 01 03 -02 01 02 01 -02 01 01 -09 10 09 00 01 00 enriched in monocytes 9.4E- 2.2E- 9.2E 4.1E- 5.5E- 1.5E- 2.5E 8.9E- 2.2E- 1.9E 2.4E- 3.8E- 1.0E+ 9.9E- 1.0E+ (surface) (M118.1) 01 01 -03 01 01 01 -01 01 01 -06 05 06 00 01 00 enriched in myeloid cells and monocytes 6.4E- 7.5E- 7.4E 4.4E- 9.7E- 1.8E- 4.7E 9.8E- 4.1E- 3.5E 1.0E- 4.3E- 1.0E+ 1.0E+ 1.0E+ (M81) 01 01 -03 02 01 01 -01 01 01 -06 08 08 00 00 00 enriched in naive and 7.2E- 8.5E- 6.5E 4.6E- 1.1E- 1.6E- 7.0E 7.2E- 9.4E- 5.0E 6.7E- 3.4E- 1.0E+ 9.9E- 1.0E+ memory B cells (M83) 01 01 -01 01 01 01 -01 01 01 -01 01 02 00 01 00 enriched in neutrophils 7.1E- 6.8E- 4.7E 6.0E- 4.5E- 3.9E- 4.2E 1.4E- 1.2E- 2.4E 1.5E- 1.7E- 1.0E+ 9.9E- 1.0E+ (I) (M37.1) 01 04 -03 01 03 01 -02 01 02 -05 01 03 00 01 00 enriched in neutrophils 7.1E- 1.2E- 5.5E 2.8E- 7.0E- 1.1E- 4.7E 3.7E- 3.0E- 6.5E 2.2E- 6.3E- 1.0E+ 9.9E- 1.0E+ (II) (M163) 01 03 -03 01 01 01 -01 01 01 -05 02 03 00 01 00 enriched in NK cells (I) 7.0E- 6.8E- 5.4E 2.4E- 1.3E- 3.9E- 7.1E 8.4E- 4.4E- 8.3E 2.4E- 5.1E- 1.0E+ 1.0E+ 1.0E+ (M7.2) 01 04 -01 03 03 01 -02 01 01 -09 07 09 00 00 00 enriched in NK cells (II) 9.7E- 7.5E- 1.2E 2.3E- 5.1E- 6.4E- 8.6E 6.1E- 5.6E- 4.3E 3.9E- 1.3E- 1.0E+ 9.9E- 1.0E+ (M61.0) 01 01 -01 02 05 03 -01 01 01 -01 02 06 00 01 00 enriched in NK cells (III) 9.4E- 6.0E- 9.4E 4.6E- 2.7E- 9.2E- 5.5E 7.8E- 8.3E- 6.7E 4.8E- 1.6E- 1.0E+ 9.9E- 1.0E+ (M157) 01 01 -01 01 02 01 -01 01 01 -03 02 05 00 01 00 enriched in NK cells (KIR 9.4E- 5.4E- 3.6E 3.1E- 5.4E- 3.2E- 4.9E 5.1E- 9.7E- 7.4E 3.0E- 2.1E- 1.0E+ 9.9E- 1.0E+ cluster) (M61.1) 01 02 -02 01 04 02 -01 01 01 -01 01 02 00 01 00 enriched in NK cells (receptor activation) 9.7E- 1.5E- 3.6E 2.3E- 8.2E- 5.1E- 6.6E 6.8E- 5.1E- 7.3E 2.2E- 1.4E- 1.0E+ 9.9E- 1.0E+ (M61.2) 01 01 -02 01 03 02 -01 01 01 -01 02 03 00 01 00 enriched in nuclear pore complex interacting proteins 6.4E- 3.0E- 4.8E 4.5E- 2.7E- 7.9E- 1.6E 4.9E- 5.7E- 6.2E 1.7E- 3.1E- 1.0E+ 9.9E- 1.0E+ (M247) 01 03 -03 01 01 03 -01 01 01 -02 02 01 00 01 00 enriched in plasma membrane proteins (I) 9.7E- 4.9E- 7.7E 7.6E- 8.8E- 3.5E- 8.4E 8.9E- 6.9E- 9.1E 8.8E- 9.7E- 1.0E+ 9.9E- 1.0E+ (M135.0) 01 02 -01 01 01 01 -01 01 01 -01 01 01 00 01 00 enriched in plasma membrane proteins (II) 9.7E- 4.7E- 7.0E 6.5E- 7.7E- 5.2E- 4.7E 8.5E- 4.3E- 7.7E 5.1E- 2.2E- 1.0E+ 9.9E- 1.0E+ (M135.1) 01 02 -01 01 01 01 -01 01 01 -01 01 01 00 01 00 enriched in T cells (I) 6.4E- 6.8E- 1.0E 2.0E- 1.4E- 2.6E- 9.1E 4.6E- 2.4E- 1.8E 1.0E- 5.2E- 1.0E+ 9.9E- 1.0E+ (M7.0) 01 04 -03 01 04 01 -01 01 02 -07 09 11 00 01 00 enriched in T cells (II) 9.4E- 1.9E- 5.5E 4.8E- 3.9E- 4.7E- 1.8E 8.9E- 6.0E- 8.2E 2.8E- 1.4E- 1.0E+ 9.9E- 1.0E+ (M223) 01 03 -03 01 02 03 -01 01 01 -06 03 04 00 01 00 erythrocyte 7.0E- 9.3E- 2.4E 2.4E- 7.4E- 3.9E- 2.6E 3.0E- 7.0E- 6.1E 1.4E- 6.9E- 1.0E+ 9.9E- 1.0E+ differentiation (M173) 01 03 -02 01 02 02 -01 01 01 -03 01 01 00 01 00 extracellular matrix (I) 7.0E- 8.5E- 8.6E 3.9E- 9.1E- 9.3E- 8.7E 8.6E- 7.5E- 2.9E 3.6E- 3.8E- 1.0E+ 9.9E- 1.0E+ (M2.0) 01 01 -01 01 01 01 -01 01 01 -01 02 02 00 01 00 extracellular matrix (II) 8.0E- 1.5E- 2.4E 3.7E- 3.7E- 2.3E- 1.1E 9.8E- 5.9E- 1.5E 6.2E- 1.7E- 1.0E+ 9.9E- 1.0E+ (M2.1) 01 03 -02 01 01 03 -01 01 01 -07 06 04 00 01 00 extracellular matrix, 7.0E- 5.6E- 1.3E 3.1E- 5.4E- 1.9E- 5.0E 9.9E- 8.8E- 6.3E 5.5E- 2.5E- 1.0E+ 9.9E- 1.0E+ collagen (M210) 01 03 -02 01 03 02 -01 01 01 -02 02 02 00 01 00 extracellular matrix, 8.4E- 4.2E- 1.3E 5.9E- 3.9E- 1.2E- 3.7E 9.4E- 5.5E- 3.0E 5.8E- 2.7E- 1.0E+ 9.5E- 1.0E+ complement (M140) 01 03 -02 01 01 01 -01 01 01 -04 02 02 00 01 00 formyl peptide receptor mediated neutrophil 8.8E- 6.8E- 1.4E 3.7E- 1.8E- 9.5E- 5.1E 9.4E- 6.3E- 2.4E 3.2E- 7.6E- 1.0E+ 9.9E- 1.0E+ response (M11.2) 01 04 -03 01 02 04 -02 01 01 -05 03 04 00 01 00 G protein mediated calcium signaling 7.1E- 8.1E- 2.5E 2.4E- 4.6E- 8.4E- 4.7E 8.9E- 9.4E- 1.1E 8.9E- 1.0E- 1.0E+ 1.0E+ 1.0E+ (M159) 01 01 -01 01 01 01 -01 01 01 -02 03 02 00 00 00 glycerophospholipid 9.4E- 7.9E- 1.2E 4.7E- 2.5E- 4.6E- 1.6E 9.2E- 6.7E- 2.8E 1.1E- 6.3E- 1.0E+ 9.9E- 1.0E+ metabolism (M114.1) 01 02 -01 01 01 01 -01 01 01 -01 02 01 00 01 00 golgi membrane (I) 8.0E- 7.7E- 8.2E 9.1E- 2.3E- 6.6E- 8.4E 8.9E- 3.0E- 5.2E 4.5E- 1.9E- 1.0E+ 9.9E- 1.0E+ (M113) 01 01 -01 01 02 01 -01 01 01 -02 03 01 00 01 00 golgi membrane (II) 9.4E- 9.6E- 5.0E 6.9E- 2.0E- 3.3E- 3.2E 7.6E- 6.3E- 2.7E 2.5E- 1.2E- 1.0E+ 8.7E- 1.0E+ (M237) 01 04 -04 02 05 06 -02 01 01 -07 01 02 00 01 00 growth factor induced, enriched in nuclear receptor subfamily 4 6.4E- 1.3E- 8.2E 4.8E- 3.2E- 2.0E- 2.4E 8.0E- 9.7E- 2.1E 9.2E- 5.6E- 1.0E+ 9.9E- 1.0E+ (M94) 01 03 -02 01 01 01 -01 01 01 -03 01 03 00 01 00 heme biosynthesis (I) 3.2E- 1.5E- 5.7E 6.0E- 7.8E- 5.8E- 2.2E 4.3E- 3.9E- 6.9E 8.3E- 1.4E- 1.0E+ 9.5E- 1.0E+ (M171) 01 01 -02 01 02 01 -01 02 01 -04 04 01 00 01 00 heme biosynthesis (II) 8.5E- 4.4E- 6.0E 4.0E- 1.6E- 9.6E- 2.7E 7.8E- 7.2E- 3.9E 4.8E- 8.6E- 1.0E+ 9.9E- 1.0E+ (M222) 01 01 -01 01 01 01 -01 01 01 -01 02 01 00 01 00 7.1E- 5.5E- 9.1E 7.4E- 9.1E- 3.2E- 4.6E 8.9E- 9.5E- 4.1E 2.6E- 2.5E- 1.0E+ 9.9E- 1.0E+ Hox cluster I (M17.0) 01 01 -01 01 01 01 -01 01 01 -02 01 01 00 01 00 7.1E- 3.7E- 4.0E 8.6E- 2.9E- 7.2E- 7.4E 9.5E- 9.4E- 7.6E 4.7E- 4.4E- 1.0E+ 9.9E- 1.0E+ Hox cluster III (M17.2) 01 01 -02 01 01 02 -01 01 01 -01 01 01 00 01 00 9.4E- 5.3E- 2.6E 9.2E- 8.8E- 5.5E- 7.8E 8.2E- 9.2E- 7.9E 1.2E- 2.3E- 1.0E+ 9.9E- 1.0E+ Hox cluster IV (M17.3) 01 01 -01 01 01 01 -01 01 01 -01 01 02 00 01 00 9.1E- 4.5E- 3.5E 9.2E- 9.7E- 2.7E- 5.5E 7.2E- 9.0E- 9.1E 1.3E- 1.2E- 1.0E+ 9.9E- 1.0E+ Hox cluster VI (M107) 01 01 -01 01 01 01 -01 01 01 -01 01 03 00 01 00 IL2, IL7, TCR network 7.0E- 2.4E- 2.1E 5.2E- 9.2E- 9.7E- 8.0E 7.9E- 8.3E- 1.2E 5.1E- 1.5E- 1.0E+ 9.9E- 1.0E+ (M65) 01 01 -01 01 01 01 -01 01 01 -01 04 04 00 01 00 immune activation - 8.0E- 6.2E- 2.6E 9.2E- 2.5E- 5.6E- 4.1E 8.9E- 1.7E- 5.3E 8.7E- 6.7E- 1.0E+ 9.9E- 1.0E+ generic cluster (M37.0) 01 03 -01 02 02 01 -01 01 01 -11 12 10 00 01 00 immuregulation - monocytes, T and B 9.4E- 7.7E- 3.7E 5.7E- 5.5E- 6.0E- 3.9E 7.8E- 6.3E- 8.7E 1.7E- 4.3E- 1.0E+ 9.9E- 1.0E+ cells (M57) 01 03 -01 01 01 01 -01 01 01 -02 01 01 00 01 00 inflammasome receptors and signaling 7.2E- 8.7E- 9.4E 4.0E- 6.8E- 6.9E- 8.5E 8.9E- 9.4E- 6.9E 1.8E- 2.6E- 1.0E+ 9.9E- 1.0E+ (M53) 01 03 -02 01 01 02 -02 01 01 -05 02 03 00 01 00 inflammatory response 7.7E- 1.9E- 5.1E 3.9E- 2.2E- 4.4E- 2.8E 8.9E- 5.1E- 5.1E 1.2E- 2.0E- 1.0E+ 9.9E- 1.0E+ (M33) 01 03 -03 01 02 03 -01 01 01 -06 04 05 00 01 00 innate activation by cytosolic DNA sensing 9.4E- 8.1E- 4.6E 6.2E- 5.3E- 4.3E- 7.4E 6.5E- 9.0E- 4.0E 3.3E- 5.3E- 1.0E+ 9.9E- 1.0E+ (M13) 01 02 -02 01 02 02 -01 01 01 -01 01 01 00 01 00 innate antiviral 7.0E- 7.4E- 4.9E 7.4E- 3.7E- 6.8E- 4.9E 9.3E- 8.3E- 7.9E 1.4E- 9.5E- 1.0E+ 9.9E- 1.0E+ response (M150) 01 01 -02 01 01 02 -01 01 01 -01 01 01 00 01 00 inositol phosphate 7.1E- 3.6E- 3.8E 1.4E- 2.0E- 1.1E- 5.5E 4.0E- 9.8E- 2.2E 1.8E- 4.1E- 1.0E+ 9.9E- 1.0E+ metabolism (M129) 01 01 -02 01 02 03 -01 01 01 -02 01 02 00 01 00 integrin cell surface 7.1E- 1.8E- 5.2E 1.5E- 4.9E- 1.2E- 8.9E 7.1E- 7.6E- 3.3E 1.4E- 8.1E- 1.0E+ 9.9E- 1.0E+ interactions (I) (M1.0) 01 01 -03 01 01 01 -01 01 01 -01 02 03 00 01 00 integrin mediated leukocyte migration 9.9E- 1.9E- 2.6E 6.3E- 4.2E- 3.0E- 4.7E 5.6E- 5.7E- 6.3E 2.3E- 9.3E- 1.0E+ 9.9E- 1.0E+ (M39) 01 03 -03 01 04 04 -02 01 01 -03 02 01 00 01 00 integrins and cell 9.4E- 4.5E- 7.1E 4.7E- 4.3E- 1.7E- 3.8E 8.4E- 9.4E- 2.4E 9.3E- 1.2E- 1.0E+ 9.9E- 1.0E+ adhesion (M84) 01 02 -02 01 02 02 -02 01 01 -04 01 01 00 01 00 intracellular transport 7.1E- 8.3E- 1.6E 8.4E- 8.9E- 1.2E- 1.2E 7.8E- 9.4E- 1.1E 6.6E- 2.0E- 1.0E+ 7.6E- 1.0E+ (M147) 01 03 -03 02 03 05 -01 01 01 -06 01 04 00 01 00 KLF12 targets network 9.7E- 1.2E- 1.9E 6.0E- 4.2E- 2.3E- 1.6E 1.4E- 7.9E- 1.7E 7.7E- 1.1E- 1.0E+ 9.9E- 1.0E+ (M32.3) 01 02 -03 01 03 04 -01 01 01 -05 03 01 00 01 00 leukocyte activation 7.2E- 2.2E- 4.6E 6.5E- 1.3E- 3.6E- 3.2E 8.9E- 7.9E- 5.4E 1.2E- 1.8E- 1.0E+ 1.0E+ 1.0E+ and migration (M45) 01 02 -02 01 03 03 -01 01 01 -02 01 01 00 00 00 leukocyte 6.4E- 9.6E- 5.5E 2.9E- 1.3E- 2.9E- 7.1E 5.3E- 7.3E- 8.4E 7.6E- 1.9E- 1.0E+ 9.9E- 1.0E+ differentiation (M160) 01 04 -03 01 03 05 -02 01 01 -05 01 03 00 01 00 lipid metabolism, endoplasmic reticulum 7.1E- 1.3E- 5.4E 9.1E- 9.1E- 8.8E- 4.5E 8.9E- 7.9E- 1.1E 5.9E- 2.1E- 1.0E+ 9.9E- 1.0E+ (M92) 01 02 -01 01 01 01 -01 01 01 -01 02 01 00 01 00 lymphocyte generic 9.7E- 4.9E- 4.0E 1.0E+ 6.9E- 9.5E- 2.4E 5.1E- 9.4E- 5.3E 6.1E- 1.9E- 1.0E+ 9.9E- 1.0E+ cluster (M60) 01 01 -01 00 01 02 -01 01 01 -02 03 02 00 01 00 lysosomal/endosomal 8.0E- 8.6E- 3.9E 9.2E- 4.4E- 2.7E- 1.3E 6.5E- 2.9E- 1.2E 1.7E- 7.1E- 1.0E+ 9.9E- 1.0E+ proteins (M139) 01 03 -03 02 01 03 -01 01 01 -07 05 06 00 01 00 9.7E- 3.5E- 4.8E 2.4E- 7.5E- 1.0E- 1.5E 4.9E- 4.4E- 3.0E 2.7E- 2.8E- 1.0E+ 9.9E- 1.0E+ lysosome (M209) 01 01 -02 01 01 01 -01 01 01 -06 04 06 00 01 00 MAPK, RAS signaling 7.3E- 1.4E- 1.4E 1.9E- 9.9E- 2.4E- 2.5E 4.9E- 8.8E- 8.0E 7.1E- 2.1E- 1.0E+ 9.9E- 1.0E+ (M100) 01 03 -03 01 04 04 -02 01 01 -05 01 02 00 01 00 Membrane, ER proteins 7.5E- 5.5E- 8.6E 7.6E- 2.2E- 2.6E- 3.8E 9.0E- 6.6E- 4.7E 4.4E- 3.6E- 1.0E+ 1.0E+ 1.0E+ (M134) 01 01 -01 01 01 02 -01 01 01 -01 01 01 00 00 00 Memory B cell surface 9.7E- 9.0E- 2.0E 8.8E- 1.4E- 1.2E- 3.2E 8.4E- 9.8E- 5.8E 8.8E- 6.9E- 1.0E+ 9.9E- 1.0E+ signature (S9) 01 03 -01 01 02 02 -01 01 01 -02 02 01 00 01 00 MHC-TLR7-TLR8 cluster 9.3E- 1.4E- 2.0E 5.6E- 1.6E- 2.1E- 5.1E 3.0E- 9.2E- 4.1E 7.2E- 7.4E- 1.0E+ 9.9E- 1.0E+ (M146) 01 03 -03 01 02 02 -02 01 01 -07 04 03 00 01 00 mismatch repair (I) 9.6E- 6.0E- 2.4E 5.3E- 2.3E- 1.1E- 4.7E 3.0E- 6.3E- 1.0E 7.9E- 3.6E- 1.0E+ 9.9E- 1.0E+ (M22.0) 01 04 -04 02 04 05 -02 01 01 -07 01 04 00 01 00 mismatch repair (II) 8.2E- 1.8E- 7.4E 2.5E- 6.0E- 2.3E- 2.9E 4.0E- 8.5E- 1.3E 9.6E- 4.2E- 1.0E+ 9.9E- 1.0E+ (M22.1) 01 03 -04 01 02 03 -01 01 01 -04 01 02 00 01 00 mitochondrial cluster 8.0E- 1.9E- 2.8E 1.2E- 2.5E- 3.3E- 1.0E 4.9E- 9.5E- 1.8E 8.4E- 4.7E- 1.0E+ 9.9E- 1.0E+ (M235) 01 03 -03 01 04 04 -01 01 01 -06 03 05 00 01 00 mitosis (TF motif CCAATNNSNNNGCG) 9.7E- 6.8E- 4.5E 6.3E- 5.1E- 4.3E- 3.2E 2.4E- 9.5E- 1.2E 9.9E- 8.1E- 1.0E+ 8.4E- 1.0E+ (M169) 01 04 -04 02 05 06 -02 01 01 -06 01 04 00 01 00 mitotic cell cycle - DNA 7.5E- 1.5E- 7.1E 6.6E- 9.7E- 8.5E- 8.8E 6.3E- 2.8E- 3.5E 7.3E- 9.4E- 1.0E+ 9.9E- 1.0E+ replication (M4.4) 01 01 -01 01 01 01 -01 01 01 -03 02 02 00 01 00 9.6E- 1.0E+ 1.2E 8.4E- 7.6E- 9.4E- 4.1E 7.7E- 7.0E- 1.2E 1.2E- 3.4E- 1.0E+ 1.0E+ 1.0E+ mitotic cell cycle (M4.7) 01 00 -01 01 01 01 -01 01 01 -01 01 02 00 00 00 mitotic cell cycle in stimulated CD4 T cells 8.8E- 1.1E- 1.0E 9.6E- 6.9E- 6.6E- 9.1E 3.7E- 3.6E- 3.1E 5.1E- 1.9E- 1.0E+ 7.2E- 1.0E+ (M4.11) 01 02 -01 01 01 01 -01 01 01 -02 01 02 00 01 00 mitotic cell cycle in stimulated CD4 T cells 8.1E- 9.6E- 2.4E 3.9E- 5.2E- 9.3E- 9.1E 4.9E- 1.7E- 2.7E 1.5E- 8.3E- 1.0E+ 9.9E- 1.0E+ (M4.5) 01 04 -02 01 02 01 -01 01 01 -04 02 04 00 01 00 mitotic cell cycle in stimulated CD4 T cells 7.0E- 1.7E- 8.5E 6.2E- 1.6E- 1.2E- 7.0E 3.4E- 3.7E- 2.9E 9.9E- 5.0E- 1.0E+ 9.9E- 1.0E+ (M4.9) 01 02 -02 01 01 01 -01 01 01 -02 01 01 00 01 00 mitotic cell division 9.6E- 6.9E- 2.5E 8.7E- 4.2E- 1.2E- 3.9E 1.4E- 1.4E- 1.3E 4.5E- 2.9E- 1.0E+ 9.9E- 1.0E+ (M6) 01 04 -03 01 01 01 -01 01 01 -05 01 02 00 01 00 Monocyte surface 6.4E- 5.8E- 6.3E 3.7E- 4.3E- 4.3E- 5.0E 9.9E- 1.1E- 3.4E 8.7E- 3.5E- 1.0E+ 9.9E- 1.0E+ signature (S4) 01 05 -05 02 01 06 -03 01 02 -12 12 11 00 01 00 myeloid cell enriched receptors and 7.3E- 7.5E- 5.6E 1.9E- 3.7E- 3.6E- 9.1E 4.9E- 2.4E- 1.2E 7.6E- 1.1E- 1.0E+ 9.9E- 1.0E+ transporters (M4.3) 01 03 -04 01 01 03 -02 01 02 -09 09 08 00 01 00 myeloid, dendritic cell activation via NFkB (I) 7.3E- 3.7E- 1.7E 4.4E- 1.1E- 8.9E- 2.3E 9.0E- 8.3E- 1.1E 5.3E- 6.8E- 1.0E+ 9.9E- 1.0E+ (M43.0) 01 03 -02 01 03 03 -01 01 01 -03 01 02 00 01 00 myeloid, dendritic cell activation via NFkB (II) 9.4E- 2.0E- 6.8E 5.7E- 7.0E- 5.2E- 2.6E 4.9E- 8.9E- 2.1E 9.3E- 3.1E- 1.0E+ 9.9E- 1.0E+ (M43.1) 01 02 -02 01 02 01 -01 01 01 -03 01 01 00 01 00 NK cell surface 9.7E- 5.4E- 1.0E 2.7E- 9.8E- 2.4E- 2.5E 1.0E+ 9.4E- 8.4E 3.7E- 6.4E- 1.0E+ 9.9E- 1.0E+ signature (S1) 01 01 -01 03 05 01 -01 00 01 -05 03 08 00 01 00 nuclear pore complex 9.4E- 5.7E- 1.3E 1.2E- 6.8E- 1.1E- 3.4E 7.9E- 9.4E- 1.2E 1.7E- 2.7E- 1.0E+ 9.9E- 1.0E+ (M106.0) 01 03 -02 01 05 05 -02 01 01 -06 02 05 00 01 00 nuclear pore complex 9.7E- 1.3E- 9.4E 2.1E- 4.5E- 1.0E- 7.9E 8.9E- 9.4E- 2.7E 4.5E- 1.6E- 1.0E+ 9.9E- 1.0E+ (mitosis) (M106.1) 01 02 -02 01 03 03 -02 01 01 -04 01 03 00 01 00 nuclear pore, transport; mRNA splicing, 9.7E- 9.9E- 7.5E 1.9E- 3.0E- 3.1E- 4.6E 1.0E+ 9.4E- 6.0E 8.6E- 9.7E- 1.0E+ 9.9E- 1.0E+ processing (M143) 01 03 -03 01 04 05 -01 00 01 -04 02 04 00 01 00 nucleotide metabolism 7.3E- 1.4E- 5.5E 2.7E- 1.1E- 6.9E- 3.2E 4.0E- 7.0E- 2.4E 1.8E- 1.1E- 1.0E+ 9.9E- 1.0E+ (M181) 01 03 -03 01 03 04 -01 01 01 -05 02 03 00 01 00 phosphatidylinositol signaling system 6.4E- 1.2E- 1.4E 3.9E- 4.2E- 1.6E- 1.0E 4.9E- 9.6E- 4.3E 4.7E- 6.8E- 1.0E+ 7.4E- 1.0E+ (M101) 01 02 -03 02 04 05 -01 01 01 -05 01 03 00 01 00 Plasma cell surface 9.7E- 1.1E- 9.7E 8.7E- 6.9E- 7.0E- 6.1E 1.0E+ 9.2E- 1.4E 9.3E- 3.9E- 1.0E+ 9.9E- 1.0E+ signature (S3) 01 02 -01 01 01 01 -01 00 01 -01 01 01 00 01 00 plasma cells & B cells, immunoglobulins 9.7E- 2.1E- 2.1E 1.3E- 5.1E- 1.7E- 5.2E 4.9E- 2.8E- 3.3E 1.1E- 8.5E- 1.0E+ 9.9E- 1.0E+ (M156.0) 01 03 -01 03 04 03 -01 01 01 -03 07 04 00 01 00 plasma cells, immunoglobulins 9.7E- 2.3E- 3.1E 9.1E- 1.6E- 1.1E- 8.5E 9.4E- 3.5E- 7.2E 8.9E- 2.0E- 1.0E+ 9.9E- 1.0E+ (M156.1) 01 03 -01 02 02 01 -01 01 01 -03 06 02 00 01 00 plasma membrane, cell 7.0E- 3.2E- 5.8E 9.8E- 6.3E- 5.3E- 8.6E 5.5E- 7.7E- 6.5E 6.0E- 3.1E- 1.0E+ 9.9E- 1.0E+ junction (M162.0) 01 02 -03 01 01 01 -01 01 01 -02 01 01 00 01 00 platelet activation - 7.0E- 6.8E- 8.9E 4.5E- 3.5E- 1.6E- 7.4E 9.4E- 7.6E- 3.0E 2.3E- 2.8E- 1.0E+ 9.9E- 1.0E+ actin binding (M196) 01 04 -05 02 01 04 -01 01 01 -01 07 06 00 01 00 platelet activation & blood coagulation 7.0E- 2.4E- 8.5E 5.6E- 3.0E- 2.2E- 8.8E 1.0E+ 9.5E- 4.1E 5.7E- 2.3E- 1.0E+ 9.6E- 1.0E+ (M199) 01 03 -04 02 01 02 -01 00 01 -01 04 03 00 01 00 platelet activation (I) 9.7E- 1.4E- 4.8E 1.9E- 9.8E- 5.0E- 3.8E 3.7E- 9.7E- 7.0E 3.3E- 1.3E- 1.0E+ 9.9E- 1.0E+ (M32.0) 01 03 -04 01 05 05 -02 01 01 -07 01 02 00 01 00 platelet activation (II) 7.5E- 9.3E- 5.6E 4.4E- 5.2E- 1.1E- 1.7E 2.2E- 9.4E- 5.7E 4.7E- 3.2E- 1.0E+ 9.9E- 1.0E+ (M32.1) 01 04 -04 02 05 05 -02 01 01 -08 01 04 00 01 00 platelet activation (III) 8.8E- 1.7E- 1.8E 4.3E- 4.5E- 6.8E- 7.1E 9.4E- 9.4E- 1.3E 4.3E- 6.5E- 1.0E+ 9.9E- 1.0E+ (M42) 01 03 -03 01 02 02 -02 01 01 -05 03 04 00 01 00 platelet activation and 7.0E- 4.9E- 8.7E 2.1E- 1.5E- 9.2E- 5.3E 9.8E- 8.3E- 1.3E 3.5E- 6.5E- 1.0E+ 9.9E- 1.0E+ degranulation (M85) 01 01 -01 01 01 01 -01 01 01 -02 04 04 00 01 00 PLK1 signaling events 9.4E- 6.8E- 2.7E 5.6E- 5.9E- 2.6E- 3.3E 3.4E- 5.1E- 1.2E 9.6E- 6.6E- 1.0E+ 9.9E- 1.0E+ (M4.2) 01 04 -02 01 01 01 -01 01 01 -04 01 02 00 01 00 proinflammatory cytokines and 8.0E- 1.2E- 2.6E 9.5E- 6.9E- 1.8E- 5.5E 8.3E- 9.0E- 3.9E 4.7E- 6.6E- 1.0E+ 9.9E- 1.0E+ chemokines (M29) 01 03 -01 01 01 01 -01 01 01 -01 01 01 00 01 00 proinflammatory dendritic cell, myeloid 9.1E- 2.2E- 2.8E 8.8E- 2.6E- 2.6E- 6.7E 9.9E- 9.2E- 4.2E 3.3E- 9.4E- 1.0E+ 7.6E- 1.0E+ cell response (M86.1) 01 02 -01 01 01 01 -01 01 01 -01 01 02 00 01 00 7.0E- 6.8E- 5.6E 6.9E- 1.1E- 6.3E- 7.6E 1.6E- 9.5E- 4.1E 1.5E- 2.9E- 1.0E+ 6.3E- 1.0E+ proteasome (M226) 01 04 -04 02 03 05 -02 01 01 -07 01 04 00 01 00 purine nucleotide 6.4E- 5.6E- 8.6E 6.9E- 5.0E- 3.7E- 4.9E 6.5E- 2.7E- 3.2E 2.2E- 2.0E- 1.0E+ 7.6E- 1.0E+ biosynthesis (M212) 01 03 -03 02 02 01 -01 02 01 -05 02 05 00 01 00 putative targets of 6.4E- 7.0E- 4.7E 4.6E- 2.2E- 1.4E- 1.2E 9.5E- 6.9E- 1.1E 7.7E- 7.7E- 1.0E+ 9.9E- 1.0E+ PAX3 (M89.0) 01 04 -02 01 01 03 -01 01 01 -02 01 03 00 01 00 putative targets of 6.4E- 2.1E- 7.4E 4.1E- 3.1E- 1.6E- 1.2E 8.0E- 5.1E- 1.0E 9.7E- 2.3E- 1.0E+ 9.9E- 1.0E+ PAX3 (M89.1) 01 03 -02 01 02 03 -01 01 01 -02 01 02 00 01 00 RA, WNT, CSF receptors network (monocyte) 6.4E- 6.8E- 4.6E 5.9E- 7.0E- 8.0E- 1.2E 6.2E- 4.1E- 1.4E 6.3E- 1.0E- 1.0E+ 9.9E- 1.0E+ (M23) 01 04 -02 01 01 02 -01 01 01 -04 01 03 00 01 00 Ran mediated mitosis 6.4E- 6.6E- 2.6E 8.5E- 8.3E- 9.2E- 6.8E 4.9E- 7.7E- 4.1E 2.4E- 4.6E- 1.0E+ 9.9E- 1.0E+ (M15) 01 03 -01 01 01 01 -01 01 01 -02 01 01 00 01 00 recruitment of 9.7E- 2.6E- 3.8E 9.1E- 5.4E- 3.4E- 4.9E 4.9E- 5.0E- 6.2E 4.1E- 4.0E- 1.0E+ 9.9E- 1.0E+ neutrophils (M132) 01 03 -02 01 01 01 -02 01 01 -03 01 01 00 01 00 regulation of antigen presentation and immune response 9.7E- 9.6E- 6.2E 9.7E- 6.3E- 4.6E- 8.7E 1.0E+ 9.9E- 4.1E 4.7E- 6.5E- 1.0E+ 9.9E- 1.0E+ (M5.0) 01 04 -03 01 01 01 -02 00 01 -07 02 04 00 01 00 regulation of 7.1E- 5.6E- 1.4E 1.0E- 4.2E- 3.4E- 1.4E 7.2E- 9.2E- 3.4E 9.5E- 2.8E- 1.0E+ 9.9E- 1.0E+ localization (GO) (M63) 01 03 -02 01 04 04 -01 01 01 -04 01 02 00 01 00 regulation of signal 7.0E- 6.7E- 4.3E 2.9E- 3.0E- 1.7E- 1.2E 8.1E- 4.3E- 2.7E 9.2E- 2.4E- 1.0E+ 9.9E- 1.0E+ transduction (M3) 01 03 -02 01 01 02 -01 01 01 -07 08 07 00 01 00 regulation of transcription, transcription factors 5.7E- 4.1E- 2.6E 6.9E- 9.2E- 3.0E- 5.7E 7.8E- 5.5E- 4.5E 7.8E- 6.5E- 1.0E+ 9.9E- 1.0E+ (M213) 01 01 -01 02 05 05 -01 01 01 -01 01 01 00 01 00 respiratory electron transport chain (mitochondrion) 8.3E- 7.0E- 7.4E 8.7E- 4.8E- 3.6E- 1.7E 3.7E- 8.1E- 1.8E 1.1E- 2.0E- 1.0E+ 7.4E- 1.0E+ (M216) 01 04 -04 01 01 01 -02 01 01 -04 02 02 00 01 00 respiratory electron transport chain (mitochondrion) 8.4E- 7.8E- 1.4E 6.9E- 4.7E- 2.9E- 1.7E 2.8E- 8.8E- 1.5E 3.4E- 2.0E- 1.0E+ 7.4E- 1.0E+ (M219) 01 04 -03 01 01 01 -02 01 01 -02 03 01 00 01 00 respiratory electron transport chain (mitochondrion) 7.0E- 1.9E- 4.5E 7.1E- 8.4E- 8.0E- 4.2E 3.7E- 8.4E- 9.0E 3.3E- 8.9E- 1.0E+ 7.7E- 1.0E+ (M231) 01 03 -03 01 02 01 -02 01 01 -03 01 02 00 01 00 respiratory electron transport chain (mitochondrion) 9.1E- 9.6E- 9.2E 5.9E- 6.1E- 3.9E- 1.5E 4.0E- 6.7E- 2.8E 2.5E- 4.7E- 1.0E+ 7.6E- 1.0E+ (M238) 01 04 -03 01 01 01 -02 01 01 -04 01 02 00 01 00 Resting dendritic cell 6.4E- 1.7E- 3.0E 3.8E- 2.5E- 4.2E- 6.0E 7.8E- 1.2E- 9.0E 7.6E- 7.5E- 1.0E+ 9.9E- 1.0E+ surface signature (S10) 01 01 -02 02 01 01 -01 01 01 -09 09 09 00 01 00 Rho GTPase cycle 9.9E- 5.6E- 4.2E 4.1E- 7.9E- 6.3E- 6.4E 7.1E- 8.1E- 1.8E 2.7E- 8.8E- 1.0E+ 9.9E- 1.0E+ (M4.14) 01 03 -01 01 01 01 -01 01 01 -01 01 01 00 01 00 RIG-1 like receptor 8.5E- 1.7E- 1.4E 9.2E- 8.7E- 1.9E- 4.7E 7.1E- 9.4E- 1.2E 3.2E- 5.2E- 1.0E+ 9.9E- 1.0E+ signaling (M68) 01 03 -01 01 01 01 -01 01 01 -01 01 01 00 01 00 signaling in T cells (I) 7.0E- 2.4E- 4.5E 4.0E- 5.5E- 2.4E- 2.5E 3.7E- 9.5E- 1.7E 5.2E- 5.4E- 1.0E+ 9.9E- 1.0E+ (M35.0) 01 03 -02 01 01 02 -01 01 01 -01 04 01 00 01 00 signaling in T cells (II) 9.7E- 3.3E- 1.0E 1.4E- 4.5E- 7.2E- 5.2E 8.9E- 9.4E- 2.7E 5.9E- 1.7E- 1.0E+ 9.9E- 1.0E+ (M35.1) 01 01 -01 01 03 02 -01 01 01 -01 03 03 00 01 00 small GTPase mediated signal transduction 9.4E- 1.9E- 1.4E 2.1E- 1.7E- 8.4E- 6.5E 1.4E- 9.7E- 2.9E 5.2E- 6.9E- 1.0E+ 9.9E- 1.0E+ (M215) 01 03 -03 01 02 04 -02 01 01 -05 04 01 00 01 00 7.1E- 1.9E- 1.4E 2.9E- 6.3E- 1.7E- 1.4E 3.7E- 9.4E- 2.0E 9.7E- 7.1E- 1.0E+ 5.9E- 1.0E+ spliceosome (M250) 01 03 -03 01 01 01 -01 01 01 -03 01 03 00 01 00 suppression of MAPK 7.0E- 1.9E- 2.3E 5.9E- 9.0E- 9.1E- 1.2E 5.5E- 4.1E- 1.6E 2.3E- 3.1E- 1.0E+ 9.9E- 1.0E+ signaling (M56) 01 03 -02 01 01 02 -01 01 01 -03 01 03 00 01 00 T & B cell development, 8.5E- 6.1E- 2.1E 6.8E- 9.7E- 4.1E- 7.1E 6.6E- 7.6E- 7.4E 2.3E- 5.5E- 1.0E+ 9.9E- 1.0E+ activation (M62.0) 01 01 -01 01 01 02 -01 01 01 -02 01 02 00 01 00 T cell activation (I) 6.4E- 1.4E- 2.6E 9.2E- 1.5E- 5.1E- 1.9E 8.9E- 1.1E- 3.9E 5.8E- 4.1E- 1.0E+ 9.9E- 1.0E+ (M7.1) 01 01 -01 01 02 01 -01 01 02 -02 09 09 00 01 00 T cell activation (II) 6.4E- 1.4E- 5.9E 3.9E- 4.0E- 2.4E- 9.4E 7.9E- 5.3E- 4.5E 6.8E- 8.9E- 1.0E+ 1.0E+ 1.0E+ (M7.3) 01 03 -02 01 03 01 -01 01 02 -06 08 08 00 00 00 T cell activation (III) 9.7E- 7.9E- 9.1E 9.4E- 6.3E- 9.3E- 1.2E 7.8E- 3.3E- 5.2E 7.7E- 1.6E- 1.0E+ 9.9E- 1.0E+ (M7.4) 01 01 -02 01 01 01 -01 01 02 -01 03 02 00 01 00 T cell activation (IV) 9.6E- 6.3E- 2.6E 8.7E- 9.4E- 9.9E- 7.1E 7.8E- 8.1E- 5.6E 4.7E- 5.5E- 1.0E+ 9.9E- 1.0E+ (M52) 01 02 -01 01 03 03 -02 01 01 -03 01 01 00 01 00 T cell activation and 7.0E- 8.5E- 8.3E 6.5E- 2.7E- 1.2E- 3.6E 6.1E- 3.9E- 4.6E 6.1E- 3.9E- 1.0E+ 9.9E- 1.0E+ signaling (M5.1) 01 01 -01 01 02 01 -01 01 01 -01 03 04 00 01 00 T cell differentiation 9.7E- 2.2E- 4.1E 6.0E- 7.7E- 6.3E- 5.4E 8.3E- 1.7E- 7.3E 7.7E- 2.7E- 1.0E+ 9.9E- 1.0E+ (M14) 01 01 -01 01 02 01 -02 01 01 -01 03 02 00 01 00 T cell differentiation 6.4E- 8.3E- 6.2E 6.5E- 5.8E- 6.7E- 9.1E 3.7E- 2.2E- 2.4E 2.5E- 1.7E- 1.0E+ 9.9E- 1.0E+ (Th2) (M19) 01 03 -04 01 02 01 -01 01 01 -04 02 05 00 01 00 T cell differentiation via 7.3E- 3.6E- 2.2E 9.6E- 7.9E- 9.3E- 4.7E 8.4E- 3.3E- 9.6E 3.2E- 1.7E- 1.0E+ 9.9E- 1.0E+ ITK and PKC (M18) 01 01 -02 01 02 01 -01 01 01 -02 03 04 00 01 00 T cell signaling and 9.7E- 8.7E- 2.4E 9.1E- 1.9E- 4.8E- 4.2E 8.4E- 6.0E- 2.7E 9.1E- 4.7E- 1.0E+ 9.9E- 1.0E+ costimulation (M44) 01 03 -02 01 03 03 -02 01 01 -03 01 01 00 01 00 T cell surface signature 6.4E- 9.6E- 5.6E 5.5E- 5.6E- 9.2E- 6.4E 3.7E- 2.2E- 1.4E 2.4E- 5.5E- 1.0E+ 9.9E- 1.0E+ (S0) 01 04 -04 01 01 01 -01 01 01 -06 05 07 00 01 00 T cell surface, activation 9.7E- 5.6E- 2.9E 6.8E- 3.9E- 1.6E- 8.6E 7.8E- 7.5E- 3.3E 6.9E- 2.7E- 1.0E+ 9.9E- 1.0E+ (M36) 01 03 -02 01 04 03 -02 01 01 -03 01 01 00 01 00 7.2E- 1.4E- 4.4E 7.5E- 9.4E- 9.1E- 4.1E 8.9E- 9.5E- 5.5E 3.0E- 5.3E- 1.0E+ 9.9E- 1.0E+ targets of FOSL1/2 (M0) 01 03 -01 01 01 01 -01 01 01 -01 01 01 00 01 00 TLR and inflammatory 7.0E- 1.1E- 2.2E 7.8E- 4.8E- 7.4E- 5.2E 4.9E- 3.3E- 1.8E 2.1E- 4.3E- 1.0E+ 9.9E- 1.0E+ signaling (M16) 01 04 -04 02 01 04 -02 01 02 -09 08 08 00 01 00 TLR8-BAFF network 7.0E- 7.0E- 5.7E 3.9E- 5.6E- 3.4E- 4.9E 7.1E- 5.2E- 2.4E 2.4E- 2.7E- 1.0E+ 9.9E- 1.0E+ (M25) 01 02 -01 01 01 01 -01 01 01 -04 05 04 00 01 00 transcription elongation, RNA 7.0E- 8.3E- 8.2E 4.7E- 1.1E- 1.1E- 1.7E 4.9E- 8.3E- 1.2E 2.6E- 2.4E- 1.0E+ 7.6E- 1.0E+ polymerase II (M234) 01 03 -01 01 01 03 -02 01 01 -04 01 02 00 01 00 transcription regulation in cell development 7.5E- 2.4E- 3.8E 1.4E- 5.9E- 1.4E- 4.6E 7.2E- 5.1E- 8.4E 1.5E- 1.0E- 1.0E+ 9.9E- 1.0E+ (M49) 01 01 -02 01 01 02 -01 01 01 -05 03 05 00 01 00 transcriptional targets of glucocorticoid 7.1E- 4.9E- 5.9E 3.2E- 6.8E- 2.1E- 2.9E 8.2E- 7.7E- 9.0E 5.8E- 4.5E- 1.0E+ 1.0E+ 1.0E+ receptor (M74) 01 02 -02 01 02 02 -01 01 01 -01 02 01 00 00 00 translation initiation 9.4E- 1.5E- 1.7E 4.0E- 1.6E- 1.1E- 1.6E 3.1E- 8.8E- 2.5E 7.2E- 5.1E- 1.0E+ 5.9E- 1.0E+ (M227) 01 03 -03 01 02 02 -01 01 01 -04 01 03 00 01 00 translation initiation factor 3 complex 7.0E- 1.2E- 3.4E 4.5E- 1.6E- 1.6E- 1.3E 3.7E- 7.7E- 1.5E 1.6E- 2.4E- 1.0E+ 9.9E- 1.0E+ (M245) 01 02 -02 02 02 01 -01 01 01 -02 02 03 00 01 00 transmembrane 7.1E- 1.1E- 4.2E 2.0E- 2.7E- 1.6E- 3.2E 9.5E- 5.1E- 3.6E 6.8E- 1.9E- 1.0E+ 9.9E- 1.0E+ transport (I) (M87) 01 03 -03 01 01 03 -02 01 01 -07 04 05 00 01 00 transmembrane 7.1E- 2.5E- 1.0E 3.6E- 2.3E- 2.2E- 3.8E 7.6E- 8.8E- 2.5E 7.0E- 2.1E- 1.0E+ 9.9E- 1.0E+ transport (II) (M191) 01 01 -02 01 02 04 -01 01 01 -02 01 02 00 01 00 type I interferon 6.4E- 1.6E- 7.3E 6.5E- 4.3E- 7.7E- 8.6E 9.5E- 9.8E- 4.6E 2.4E- 1.5E- 1.0E+ 9.9E- 1.0E+ response (M127) 01 01 -01 01 01 01 -01 01 01 -01 01 02 00 01 00 viral sensing & immunity; IRF2 targets 9.9E- 4.8E- 5.7E 3.9E- 3.9E- 2.6E- 5.2E 4.6E- 6.6E- 4.6E 2.2E- 7.4E- 1.0E+ 9.9E- 1.0E+ network (I) (M111.0) 01 01 -02 01 01 02 -01 01 01 -05 05 04 00 01 00 Wnt signaling pathway 7.3E- 4.9E- 3.7E 8.7E- 1.2E- 1.5E- 4.7E 8.9E- 5.7E- 7.5E 1.9E- 9.3E- 1.0E+ 9.9E- 1.0E+ (M206) 01 01 -01 01 02 01 -01 01 02 -01 01 01 00 01 00

1. Li S, Rouphael N, Duraisingham S, Romero-Steiner S, Presnell S, Davis C, Schmidt DS, Johnson SE, Milton A, Rajam G et al: Molecular signatures of antibody responses derived from a systems biology study of five human vaccines. Nature immunology 2014, 15(2):195-204. 2. Hochberg Y, Benjamini Y: More powerful procedures for multiple significance testing. Statistics in medicine 1990, 9(7):811-818.